Immunotherapy
Feature
Outpatient CAR T: Safe, Effective, Accessible
'The future of CAR T-cell therapy lies in balancing safety with accessibility,' says expert.
Feature
Many Hurdles Exist to Treating Lung Cancer With CAR T Cells
Unleashing the immune system in a highly specific manner, ‘is obviously, in a way, a holy grail’ in lung cancer, said an expert at the W...
Feature
How to Treat Cancer While Preserving Fertility
Some chemotherapies are known for their effects on oocytes, follicle maturation, and spermatogenesis, but knowledge about newer treatment options...
Latest News
Nobel Prize in Medicine Awarded to MicroRNA Researchers
Dr. Victor Ambros and Dr. Gary Ruvkun won the Nobel Prize in medicine for their discovery of microRNAs.
News from the FDA/CDC
FDA Panel Votes for Limits on Gastric, Esophageal Cancer Immunotherapy
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of restricting the use of these immunotherapy agents to patients with PD-L1...
Latest News
Melanoma: Neoadjuvant Immunotherapy Provides Optimal Survival Results
Those who received combination therapy achieved higher event- and recurrence-free survival than patients who received monotherapy.
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Latest News
Diagnosing, Treating Rashes In Patients on Immune Checkpoint Inhibitors
Cutaneous immune-related adverse events are the most frequently reported and most visible adverse effects of checkpoint inhibition.
Feature
Jeffrey Weber, MD, PhD, Giant of Cancer Care, Dies
He was a principal investigator on many studies, including pivotal clinical drug trials in melanoma.
From the Journals
Few Severe Toxicities After SBRT in Oligometastatic Cancer
SBRT, an alternative to chemotherapy and immunotherapy, offers treatment with a low rate (0.5%) of severe acute toxicities.
From the Journals
Immunotherapy and Survival in Advanced NSCLC: Does Obesity Matter?
Researchers evaluated 31,257 patients with advanced NSCLC from Japan who received immune checkpoint inhibitors or conventional chemotherapy.